Company Snapshot
Hims & Hers Health — NYSE HIMS is a consumer health platform connecting customers with clinicians, medication, diagnostics and continuing care. The investment question is whether it can turn its growing customer relationships into durable cash earnings after changing its GLP-1 business.
| Field | Current assessment |
|---|---|
| Sector | Consumer healthcare and digital health |
| Thesis status | Changed and being re-underwritten; the platform opportunity survives |
| Analytical confidence | Moderate in the platform; lower in margin recovery and organic subscriber durability |
| Time horizon | 2–3 years, with the 2030 ambitions as a longer-term checkpoint |
| Price reference | $16.02, 19 November 2026 regular-session closing price, verified 20 November |
| Latest reported quarter | Q3 2026, ended 30 September; released 9 November 2026 |
| Next quarterly results | Not yet searched — two calendar months have not elapsed since the latest results were released on 9 November 2026. |
Price history · Q2 earnings release
The platform opportunity remains credible, but the economics are unproven. More subscribers, broader care and AI could strengthen HIMS. The test is whether they improve retention, contribution profit and free cash flow as branded GLP-1s and international markets become a larger part of the business.
What matters most
- Customer growth: separate organic acquisition and retention from customers and revenue added through acquisitions.
- Growth quality: Q3 revenue rose 49%, but gross profit grew 15%, adjusted EBITDA only 5% and free cash flow fell 67% year over year.
- AI economics: early support-efficiency results are promising; durable retention and cross-sell gains remain unquantified.
- Cash conversion: Q3 free cash flow returned to positive $26.0 million, but nine-month free cash flow was only $10.8 million versus $60.0 million a year earlier; sustained conversion remains unproven.
- Execution discipline: strengthen the existing platform while managing drug, privacy and new-category risks.
The financial comparisons are calculated from the release. AI and H2 cash expectations are management statements. Q2 release · Q2 call
Investment Thesis
Thesis premise: HIMS can become a lasting consumer health platform. Customers may enter through hair loss, sexual health or weight management, then stay for additional needs as the offering broadens. AI, diagnostics and continuing care could deepen those relationships and improve the cost of serving them. The aggressive approach to compounded GLP-1s damaged credibility; the revised business must now demonstrate that the wider platform can grow and become more profitable.
Independent assessment: this remains a credible thesis, with an important change in underwriting. The previous economics of compounded weight-loss drugs cannot simply be carried forward into the branded model. HIMS must show that the customer relationship itself creates enough value to compensate for lower drug margins, higher working-capital needs and international investment.
The strongest confirming evidence is domestic revenue acceleration and restored cash generation. Q3 U.S. revenue grew 21% year over year, up from 16% in Q2, while operating cash flow was $65.4 million and free cash flow $26.0 million. Total revenue reached $890.4 million, within prior guidance. These are reported results; they do not by themselves prove organic cohort retention. Q3 release · Q3 Form 10-Q
The strongest disconfirming evidence is weaker economics and subscriber momentum. Q3 subscribers fell by about 103,000 sequentially to 2.788 million, gross margin declined to 57% from 74% a year earlier, and the full-year adjusted EBITDA outlook was reduced to $257–277 million from $275–325 million despite the larger revenue base. Management attributes the sequential subscriber decline to measured U.S. weight-loss marketing and international brand migrations; retention was not quantified. Q3 release · Q3 call transcript
Answers to the four central questions
| Question | Current answer |
|---|---|
| Can HIMS attract and retain more customers? | Q3 U.S. revenue accelerated, but subscribers fell sequentially; organic acquisition and retention remain insufficiently disclosed |
| Can it use AI effectively? | Management says the AI-native experience reached 70% of weight-loss subscribers; sustained retention and net financial benefits still need proof |
| Can it broaden the offering? | Branded access, TRT and international reach support this; profitable adoption matters more than launch count |
| Can it expand margins? | Q3 gross margin fell to 57% and full-year EBITDA guidance was reduced; recovery now requires evidence beyond revenue growth |
The potential investment edge is that HIMS could retain customers across several care categories and lower the cost of serving them enough to create a durable platform. That outcome could support substantial upside. It remains a hypothesis until cross-sell, retention and cash conversion become visible. Rising revenue alone does not establish it.
The Business
HIMS combines a consumer brand, digital intake, access to licensed clinicians, pharmacy fulfillment and ongoing support. Much of its revenue comes from recurring subscriptions, alongside consultations, products and testing-related services. Subscribers are customers with recurring billing arrangements; they can cancel or pause subscriptions. This is recurring consumer healthcare with treatment and service costs. Q2 release
The platform’s economic engines differ:
| Business area | Economic role |
|---|---|
| Established specialties | Hair loss, sexual health and other recurring treatments provide an existing customer base and opportunities for efficient fulfillment |
| Branded weight management | Expands customer reach; creates drug procurement, supplier dependence and working-capital demands |
| Diagnostics and hormonal health | May identify additional needs and deepen relationships; requires clinical oversight and evidence of profitable adoption |
| International markets | Extend the addressable market; acquisitions and local investment complicate comparisons and delay profit contribution |
In the Q1 call, management said branded medication fulfilled through HIMS pharmacies is recognized as revenue on a gross basis. Consequently, larger medication sales can increase reported revenue without an equivalent rise in contribution profit.
On 9 March 2026, HIMS announced a renewed Novo Nordisk collaboration, ended advertising of compounded GLP-1 offerings and narrowed access to compounded products to cases deemed clinically necessary by a provider. The reset changed the weight-loss business; it did not eliminate every compounding offering. Strategic shift announcement On 6 November, HIMS and Eli Lilly announced integrated access to Zepbound and Foundayo at Lilly’s self-pay prices, with eligible patients remaining inside the HIMS platform from consultation through home delivery. HIMS committed not to offer compounded copies of Lilly GLP-1s. Commercial fees, volumes and margins were not disclosed. Lilly agreement
Competitive Advantages
The most plausible advantage is the combination of brand, customer access, clinical workflow, fulfillment and continuing care. Owning more of that journey may help HIMS introduce treatments, reduce friction and learn which experiences keep customers engaged.
Its scale can also spread technology and fulfillment costs across a larger customer base. An existing relationship could make a second specialty cheaper to acquire than a new customer reached through advertising. Diagnostics could make that relationship more useful by identifying additional care needs. The Lilly agreement adds evidence that a second major branded-drug manufacturer sees value in HIMS distribution, but it is not disclosed as exclusive and its economics remain unknown. These are potential advantages; their strength depends on measured retention and contribution economics.
AI fits this model because HIMS can connect customer context with care and fulfillment. In September, the company described persistent context, provider escalation and clinical safeguards as it expanded the AI experience to Hims weight-loss members. Those are company descriptions of its system, rather than evidence of clinical superiority. September AI update
Moat assessment: promising but developing. HIMS does not own the core intellectual property of branded GLP-1 drugs. Pharmaceutical suppliers, competing telehealth platforms and other distribution channels can constrain pricing power. Scale and data become a durable moat only if customers stay and the financial advantage persists.
Growth Drivers
| Driver | Evidence and next economic test |
|---|---|
| Domestic weight loss and branded access | U.S. revenue growth accelerated to 21% in Q3. Novo and Lilly broaden the branded assortment. Test Q1 2027 subscriber recovery, retention and contribution profit |
| More needs per customer | Management plans to report more on retention and multi-condition adoption with the 2027 outlook. Test quantified multi-specialty adoption, not launch breadth |
| Testosterone, Peptides+ and diagnostics | Testosterone approached a $100 million annualized revenue run rate; injectable and oral TRT broadened the offer. Peptides+ launched with five U.S.-compounded treatments and paid Care+ on 18 November. Test repeat demand, safety outcomes and contribution margins |
| International expansion | Q3 international revenue reached $233 million, including about $135 million from Eucalyptus; the rest grew nearly 80% according to management. The UK added a free metabolic questionnaire, optional at-home testing and £39-per-month Care+ on 19 November. Test organic growth, conversion and progression toward profit |
| AI | Management says the AI-native experience reached 70% of weight-loss subscribers. Test net cost savings, measured retention and care quality |
These are reported results and management expectations from the Q2 call. HIMS also introduced its brand in Australia through the local rebrand of Pilot on 31 August. Australia announcement On 12 October, Juniper was rebranded to Hers in Australia with broader care offerings; this is integration of an acquired platform, not proof of new organic demand. Australia launch On 14 October, the company described the UK Hers Hair launch. Company update On 20 October, Hims launched weight-management care for men in Germany with prescribing decisions by EU-licensed clinicians; the announcement did not quantify adoption, revenue or profit. Germany launch On 21 October, HIMS added injectable and oral TRT. Management called this its largest men's-health expansion since entering the category and said testosterone was scaling faster than any specialty outside weight loss as of Q2. Those are management claims; the launch updates do not quantify incremental revenue, retention or profit. TRT launch On 5 November, Hims & Hers Benefits added Grüns, Medjet, Tonal and Viome and reached 14 partners. This broadens the member ecosystem, but the company disclosed no adoption, retention or revenue effect. Benefits update On 19 November, Hers UK launched a free Metabolic Deep Dive questionnaire, an optional at-home blood test and Care+ at £39 per month. This creates another recurring-care funnel, but the company reported no adoption, retention or profit evidence. UK launch
Peptides remain optional upside, not part of the base case. On 30 October, HHS published a draft, non-binding enforcement-discretion policy for 503A compounding with six peptide bulk substances while formal rulemaking continues. The interim policy may be revisited for safety or product-quality issues and is not FDA approval or a final rule. Federal Register notice On 18 November, HIMS launched Peptides+ in the U.S. with access to Sermorelin, NAD+, Glutathione, vitamin B12 and L-carnitine, plus Care+ clinical support and twice-yearly lab testing. The Hers product page advertises medication from $99 per month and Care+ at $49 per month; it also states that these emerging therapies are not FDA-approved or evaluated by the FDA and are not available in every state. BPC-157 and TB-500 remain future additions subject to regulatory standards. Commercial availability is execution evidence, not evidence of demand or economics: adoption, revenue, gross margin, cash contribution and manufacturing mix remain undisclosed. Official launch · Hers product page
Economics & Financial Profile
Q3 confirmed strong top-line demand but weaker profit conversion. Revenue accelerated, U.S. growth reached 21% and free cash flow turned positive. Against that, subscribers declined sequentially, gross margin fell to 57%, GAAP losses continued and full-year adjusted EBITDA guidance was reduced. Management says branded international weight loss was the main gross-margin drag and expects the rate of decline to moderate; that is guidance, not a reported recovery.
| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | $890.4m | $599.0m |
| U.S. revenue | $657.1m | $543.5m |
| Rest-of-world revenue | $233.3m | $55.5m |
| Subscribers | 2.788m | 2.471m |
| Monthly revenue per average subscriber | $105 | $81 |
| Gross profit | $509.2m | $442.1m |
| Gross margin | 57% | 74% |
| Adjusted EBITDA | $82.4m | $78.4m |
| Adjusted EBITDA margin | 9% | 13% |
| GAAP net income | −$33.0m | $15.8m |
| Operating cash flow | $65.4m | $148.7m |
| Free cash flow | $26.0m | $79.4m |
| Stock-based compensation | $64.5m | $40.2m |
Q3 release and reconciliations · Official release · Q3 Form 10-Q
Three distinctions matter:
Revenue per subscriber is not profit per subscriber. Monthly revenue per average subscriber rose from $81 to $105, but about $10 of the Q3 2026 metric came from one-time purchasers. Multiplying the reported figures by gross margin gives an illustrative monthly gross-profit proxy of roughly $60 versus $60. That is essentially flat despite 30% higher revenue per average subscriber. This blended proxy is not a cohort contribution-margin calculation.
Management’s presentation adds supportive but incomplete unit-economics evidence. It presents 85%+ long-term online revenue retention for subscriptions with at least two years of tenure and 6–8 month payback periods for the Q1 acquisition cohorts from 2021 through 2025. These are company-defined management metrics and selected cohorts, not current total subscriber retention, specialty-level CAC or full contribution economics. They improve the evidence set but do not resolve the Q3 sequential subscriber decline or the gap between revenue and gross-profit growth. Official Q3 presentation
Adjusted EBITDA needs a cash bridge. Q3 adjusted EBITDA was $82.4 million, but stock-based compensation was $64.5 million, acquisition/transaction/earn-out costs were $35.4 million and depreciation/amortization was $38.2 million. Q3 free cash flow recovered to $26.0 million, while nine-month FCF was only $10.8 million versus $60.0 million a year earlier. The return to positive quarterly FCF is evidence of improvement; its durability and per-share value remain open tests. Q3 release
The September balance sheet held $712.2 million in cash and short-term investments against $1.367 billion of convertible notes at carrying value, $563.1 million of deferred acquisition payables and $170.8 million of earn-out liabilities. HIMS also had $161 million available under its revolver, with no loans outstanding. Contractual obligations due within 12 months totaled $607.0 million. Liquidity is meaningful, but acquisition payments and possible equity settlement keep dilution and financing risk material. Q3 Form 10-Q
Key KPIs
Analyst-proposed monitoring tests below are draft decision aids, not approved trading rules. Review them with each earnings release and call.
| KPI | Latest baseline | Next proof point |
|---|---|---|
| U.S. revenue growth | +21% in Q3, after +16% in Q2 | Sustain at least mid-teens growth with mix and organic contribution explained |
| Subscribers | 2.788m, +13% year over year but −103k sequentially | Recover sequential growth and quantify organic additions, churn and acquired customers |
| Gross profit | $509.2m, +15% | Close the gap with 49% revenue growth through better contribution economics |
| Gross margin | 57% | Establish a post-reset floor and demonstrate moderation of the decline |
| Retention and cross-sell | Management presents 85%+ long-term online revenue retention for subscriptions with at least two years of tenure; current total subscriber retention is not disclosed | Disclose current organic cohort retention, churn, cancellation changes and multi-specialty adoption |
| AI efficiency | AI-native experience reached 70% of weight-loss subscribers, per management | Show net cost-to-serve savings, measured retention and stable care quality |
| Adjusted EBITDA margin | 9% Q3; 8–9% FY guidance | Deliver Q4 guidance and a credible 2027 recovery path |
| Free cash flow | $26.0m Q3; $10.8m YTD | Positive H2 and 2027 FCF without relying on working-capital timing |
| International profitability | $233m Q3 revenue, acquisition-heavy | Separate organic growth and show contribution toward profit |
| Dilution and obligations | 234.4m shares at September end; $607m obligations due within 12 months | Track shares, acquisition payments, notes and liquidity together |
Baselines: Q2 release · Q2 call.
Management’s early AI figures—3× as many messages, 80% of questions answered by AI and nearly 50% less specified nonclinical support work—relate to a phased Hers weight-loss rollout beginning in July, after Q2 ended. They do not imply a 50% reduction in total costs. Earlier internal AI work and pharmacy throughput also contributed to Q2 leverage. Lower cancellations were described without a quantified cohort comparison. Q2 call
Management & Capital Allocation
Andrew Dudum has built a recognizable consumer platform and repeatedly expanded its offering. The same willingness to move quickly created material risk around compounded GLP-1s. The evaluation now rests on how management balances speed with clinical quality, partner relationships and regulatory discipline.
The March reset is a constructive adjustment. Waiting for final FDA rulemaking on the pending peptides is also a positive signal of restraint. However, neither restores conviction by itself. Credibility improves when promises about retention, investment payback and cash generation become measurable results. Strategic shift · Q2 call
7 October update — accounting leadership: HIMS appointed Jon Franklin as Chief Accounting Officer, reporting to CFO Yemi Okupe and succeeding Irene Becklund, who will advise on the transition. The 7 October Form 8-K confirms the principal-accounting-officer appointment took effect on 9 October and Becklund’s advisory agreement runs from 10 October 2026 through 10 July 2027. This provides continuity in financial reporting; improved execution or cash conversion must still be demonstrated. Company announcement, 7 October 2026 · Form 8-K, 7 October 2026; checked 11 October On 2 November, HIMS named Ajay Mittal its first Chief Business Officer, responsible for U.S. strategy and growth. His operating background may support integration, but the new role is a management claim and organizational change, not evidence of improved execution. CBO appointment
9 November update — board and marketing arrangements: On 4 November, the board expanded from nine to ten members and appointed Dr Andrew Huberman, whom the board determined is not independent under NYSE standards. The related Form 8-K discloses a $50,000 annual cash retainer and a $250,000 equity award, prorated through the 2027 annual meeting, plus a two-year advisory agreement at $3.5 million per year, optional short-form advertising videos up to $1.0 million per year, and a podcast advertising agreement of up to three years at $5.0 million per year with Scicomm Media, which Huberman co-owns. His scientific reach may strengthen brand and product communication, but the return is unproven and the combined director/adviser/marketing relationship increases governance scrutiny. These are disclosed contractual facts; business benefit remains an analytical question. Company announcement, 9 November 2026 · Form 8-K, dated 4 November 2026
Capital allocation is demanding: integrate Eucalyptus, fund international expansion, build AI and diagnostics, meet acquisition obligations and manage dilution. The July receivables program has a $400 million limit and is uncommitted: eligible receivables may be sold at a discount, so this is not guaranteed cash. The $402.5 million convertible issue occurred in May and is already in the June balance sheet. It must not be added again. Management reported $225 million remaining under the repurchase authorization at Q2. The investment case still needs internally generated cash. Q2 call · Q2 10-Q, notes 13 and 20
Management standard: clearer unit economics, fewer recurring “one-time” adjustments and a visible link from capital invested to cash earnings per share.
Risks / Bear Case
The strongest bear case is a growing platform with disappointing incremental cash earnings. HIMS could successfully attract customers while pharmaceutical suppliers capture much of the value, international investment absorbs profits and cross-sell fails to offset lower drug margins.
- Supplier and distribution risk: the Lilly agreement improves branded-drug access, but the products remain available through other channels and HIMS disclosed no exclusivity or unit economics. Branded access still depends on suppliers that retain negotiating leverage.
- Growth-quality risk: acquisitions and gross medication revenue can make expansion look stronger than the underlying economics.
- Regulatory and clinical risk: compounding, hormonal therapies and new categories require disciplined execution; adverse events or restrictions could damage trust.
- Privacy and subscription risk: the FTC case alleges improper sharing of sensitive health information and deceptive billing/cancellation practices. On 10 November, the FTC filed an amended complaint adding Arizona, Florida, Nebraska, Ohio and Wisconsin as co-plaintiffs alongside the original government plaintiffs, broadening the alleged state-law exposure; the case remains pending. HIMS disputes the allegations. A related securities class-action complaint, Velanki v. Hims & Hers Health, Inc., was filed on 1 September; the accessible docket does not establish liability. These are allegations, not findings. FTC case and amended complaint · FTC announcement, 10 November 2026 · Company response · Court docket
- AI risk: mistakes, weak escalation or privacy failures could offset efficiency benefits. More engagement is valuable only when it improves care and economics.
- Capital risk: receivables, acquisition payments, debt and equity compensation can reduce shareholder returns even when adjusted EBITDA grows.
A further risk is thesis drift: replacing each unresolved profit question with the next large market opportunity. The existing customer base should prove its value before new categories carry the valuation.
Valuation
ChatGPT produces the calculations and valuation scenarios. Share-price inputs are dated to the analysis; they are not continuously updated market data.
Different outcomes. Different values.
$16.02 USD · 19 Nov 2026 · 16:00 EST · close
Price attractiveness
Price attractiveness: 4,8/10 at 16.02 USD. Quote date: 19 November 2026, last regular-session closing price, 4:00 p.m. EST. Evaluated on: 20 November 2026. Security: Hims & Hers Health, Inc., NYSE: HIMS, Class A common stock. Horizon: three years, to 20 November 2029. Methodology: 1.2. Price history
Reference price: $16.02. Using 234.4 million September-end shares across Classes A and V gives approximately $3.76 billion of equity value. Adding convertible notes at carrying value and subtracting cash/investments produces approximately $4.41 billion of enterprise value. Including deferred acquisition and earn-out liabilities as debt-like obligations raises the analytical value to about $5.14 billion. This is an analyst bridge using the September balance sheet, not a provider EV. Operating leases are excluded. Price history · Q3 Form 10-Q
Against the $3.14 billion revenue and $267 million adjusted EBITDA midpoints of revised 2026 guidance, the obligation-inclusive bridge is approximately 1.6× revenue and 19.3× adjusted EBITDA. The revenue multiple is lower after the selloff, but the earnings multiple still assumes that depressed margins recover and that recurring adjustments do not consume the economic profit.
Three-year scenarios to 20 November 2029
These are analyst assumptions and terminal values, not company guidance, consensus forecasts or near-term price targets. The 2029 annual operating figures are proxies for the business at the horizon date; they are not forecasts already reported by the company.
| Assumption or output | Adverse | Base | Bull |
|---|---|---|---|
| Revenue | $3.6bn | $4.7bn | $5.8bn |
| Revenue CAGR from revised 2026 guidance midpoint | 5% | 14% | 23% |
| Adjusted EBITDA margin | 7% | 12% | 17% |
| Adjusted EBITDA | $252m | $564m | $986m |
| EV / adjusted EBITDA | 10× | 17× | 22× |
| Assumed shares | 280m | 265m | 260m |
| Net obligations, using note principal | $1.424bn | $1.424bn | $1.424bn |
| Estimated price in three years | 3.91 USD | 30.81 USD | 77.95 USD |
| Assumed dividends over three years | 0 USD | 0 USD | 0 USD |
| Total three-year return from 16.02 USD | −75.6% | +92.3% | +386.6% |
| Annualized return | −37.5% | +24.4% | +69.5% |
Formula: share value = (revenue × EBITDA margin × multiple − 1.424143 billion USD net obligations) ÷ assumed shares. Total return = (terminal share value + cumulative dividends) ÷ 16.02 USD − 1; annualized return = (1 + total return)^(1/3) − 1. Returns use unrounded values and are before taxes, fees and currency translation, with no dividend reinvestment.
The terminal bridge uses 1.4025 billion USD of note principal, rather than carrying value, plus September deferred acquisition payables and earn-outs, less September cash/investments: 1.424143 billion USD. Net obligations stay constant: retained cash is assumed to fund reinvestment rather than reduce net debt. Share assumptions allow equity-compensation dilution; acquisition obligations are treated as cash-settled and notes remain debt, without also adding conversion shares. Equity settlement, further cash burn, note conversion or new acquisitions would require rebuilding both obligations and share counts. These are simplified sensitivities, not a full cash-flow model. Q3 Form 10-Q
The adverse case assumes subscriber weakness, lasting gross-margin pressure, limited EBITDA recovery and a lower multiple. The base case assumes mid-teens revenue growth from revised 2026 guidance and gradual recovery to a 12% EBITDA margin. The bull case requires stronger retention, cross-sell and operating leverage. The reduced 10×/17×/22× multiples and lower margin assumptions reflect the Q3 evidence; they are analytical judgments, not company guidance.
Independent valuation assessment: the selloff creates more upside if the platform economics mature, but Q3 also weakened the margin case. The base illustration yields roughly 24.4% annualized over three years, while the adverse case loses about three-quarters of value. Management’s 2030 ambition of at least $6.5 billion revenue and $1.3 billion adjusted EBITDA remains an ambition until retention, margins and cash earnings establish that trajectory.
- Short rationale: The 19 November close is 18.8% below the 13 November reference, 38.4% below the 6 November close and 48.2% below the 9 October close. Q3 revenue and cash flow were better than the Q2 trough, but subscriber contraction, 57% gross margin and reduced EBITDA guidance still require lower terminal margins and multiples. Unchanged operating assumptions now give a base return of +92.3% over three years (24.4% annualized), against −75.6% in the adverse case. Price attractiveness rises to 4,8/10: the lower quote materially improves upside, but the still-severe adverse outcome and low-confidence operating assumptions keep the risk/reward below the methodology’s approximately-fair 5–6 band.
- Main weakness: The valuation is highly sensitive to margin recovery, subscriber retention, dilution and the treatment of acquisition obligations; failure to rebuild economics can overwhelm the lower entry price.
- Confidence: Low; the 19 November closing quote and Q3 accounts are verified, but future margins, retention, share counts and valuation multiples remain uncertain.
- Change condition: Sustained subscriber recovery, positive FCF and improving gross-profit conversion at a similar price would raise the score. Further guidance cuts, more dilution or a price recovery without better economics would reduce it.
- Sources: Q3 results for the quarter ended 30 September 2026, released 9 November; Q3 Form 10-Q; Q3 management call transcript; and the 19 November closing quote, checked 20 November and corroborated by a second historical-price source. Links and coverage are recorded below. Methodology: 1.2.
What Would Change the Assessment?
Evidence that would strengthen conviction
- Two quarters of sustained domestic growth accompanied by stronger gross-profit growth and improving contribution economics.
- Positive H2 2026 free cash flow, followed by healthy conversion during 2027.
- Quantified retention and cross-sell gains that survive beyond early pilot cohorts.
- Net AI savings after development and oversight costs, with service quality maintained.
- International operations becoming meaningful profit contributors rather than relying on continuing acquisitions.
Evidence that would weaken or break the thesis
- Two successive quarters of stagnating organic customer growth while acquisition spending remains heavy.
- Repeated gross-margin deterioration without compensating gains in contribution profit.
- Continued cash consumption after the promised recovery, with financing masking poor economics.
- Material restrictions or failures that undermine customer trust, drug access or the ability to use data responsibly.
- Further aggressive launches that recreate the GLP-1 credibility problem.
- A widening gap between adjusted EBITDA growth and value created per share.
These are draft analyst tests. A lower gross margin alone does not break the thesis if contribution dollars, retention and cash improve.
Current View
Wait for operating proof. The platform opportunity remains credible, and domestic recovery supports continued analytical attention. The reset has changed the financial model enough to require fresh underwriting. This is a business still demonstrating its earning power.
The company thesis is changed, with customer reach improving and the long-term margin thesis unproven. The stock thesis is conditional: valuation can work well under strong execution, but even the lower price does not establish a margin of safety under average execution.
Business strength
Business strength: 5,1/10. Evaluated on: 20 November 2026. Methodology: 1.2, effective 16 October. Each component has a 20% weight; (5,2 + 7,6 + 3,9 + 3,6 + 5,0) ÷ 5 = 5,1 after rounding. Ratings use the required 1–10 scale and one decimal place. The stock price and ownership do not enter this score.
| Area | Score | Main evidence |
|---|---|---|
| Competitive advantage | 5,2/10 | Q3 scale, 21% U.S. revenue growth and relationships with Novo and Lilly support distribution credibility. Non-exclusivity, a sequential subscriber decline and missing retention/cross-sell economics limit the moat evidence. |
| Demand durability | 7,6/10 | Revenue grew 49% and subscribers 13% year over year, but subscribers fell about 103,000 sequentially. Management presents 85%+ long-term online revenue retention for subscriptions with at least two years of tenure; current organic subscriber retention is not disclosed. |
| Management execution | 3,9/10 | Q3 revenue met guidance and FCF turned positive, but gross margin fell sharply and full-year EBITDA guidance was reduced. The 18 November Peptides+ launch adds product-delivery evidence, not adoption or economic proof; the Huberman arrangements remain a governance test and Q1 2027 operating delivery the main score driver. |
| Business economics | 3,6/10 | Q3 gross margin was 57% versus 74%, adjusted EBITDA margin 9% versus 13%, GAAP loss $33.0 million and FCF $26.0 million. Management presents 6–8 month payback for selected Q1 cohorts; broad per-share value creation remains unproven. |
| Financial resilience | 5,0/10 | September cash/investments of $712.2 million plus $161 million revolver availability provide liquidity. This is balanced by notes, $607 million of obligations due within 12 months and potential dilution. |
- Short rationale: Q3 strengthens the evidence for revenue demand and restores positive quarterly FCF, but it weakens the economics and retention case. Demand durability, management execution and business economics remain lower because subscribers declined sequentially, gross margin compressed to 57% and EBITDA guidance was cut. The 18 November Peptides+ launch and 19 November UK metabolic/Care+ launch show product execution, but disclose no adoption, margin or cash contribution. The official Q3 presentation’s retention and payback metrics, the amended FTC complaint and the Huberman arrangements improve evidence quality and risk coverage without justifying a change to any component. The weighted score therefore remains 5,1/10; the share price does not affect this business score.
- Main weakness: Customer and revenue growth may fail to create durable cash earnings per share.
- Confidence: Medium; the Q3 release, 10-Q and call provide current evidence for all five areas, but cohort retention, organic subscriber growth and contribution economics remain insufficiently quantified.
- Change condition: Two reported quarters with recovering organic subscribers, improving gross-profit conversion and positive FCF, plus quantified retention or multi-specialty economics, would support an increase. Further subscriber contraction, margin erosion, dilution or financing pressure would support a decrease.
- Sources: Q3 release, released 9 November 2026 for the quarter ended 30 September; official release; Q3 Form 10-Q; official Q3 call transcript; official Q3 presentation; Huberman appointment and agreements, Form 8-K; and FTC amended case record; Peptides+ launch, 18 November; and UK metabolic/Care+ launch, 19 November. All three exact Page file references were reread successfully on 20 November. Reported results, management claims and analytical assumptions are separated above.
For the next review, compare Q4 with management’s $875–895 million revenue and $70–90 million adjusted EBITDA outlook. The main tests are sequential subscriber recovery, gross-margin stabilization, positive full-year FCF and the 2027 outlook for retention and international investment. Next quarterly results: not yet searched — two calendar months have not elapsed since the Q3 results were released on 9 November 2026.
A stronger investment case would require operating proof and attractive valuation together. Failure to deliver H2 cash recovery should trigger re-underwriting; persistent economic deterioration or another material breach of execution discipline would materially weaken the case.
The question to keep asking: how much durable cash profit does the next customer relationship create?
Thesis History / Updates
| Date or period | Development | Thesis implication |
|---|---|---|
| 9 March 2026 | Novo collaboration and shift toward approved branded GLP-1s | Rebuild weight-loss economics under the revised model |
| Q1 2026, discussed in May | Transition costs, margin pressure and a 2027 profitability expectation | Treat recovery as a delivery requirement |
| Q2 2026, released 10 August | Domestic reacceleration and broader international footprint; weaker profit conversion | Growth case improves; margin case remains unproven |
| August–September 2026 | Early AI support metrics and broader rollout | Operational evidence improves; retention and cash tests remain open |
| 7 October 2026 | Initial investment card established | Preserve falsifiable operating tests; platform economics still require proof |
| 10 October 2026 | Partial evidence review; CAO appointment added, financing clarified and closing quote updated. First scores under methodology 1.0: Business strength 5.2/10; price attractiveness 3/10 at 30.92 USD, close 9 October | Qualitative platform thesis retained. Base three-year return +22.0%; adverse −73.9%. Terminal note principal replaces carrying value; operating scenario assumptions retained |
| 11 October 2026 | Partial follow-up since 10 October; SEC transition dates clarified. Methodology 1.0 unchanged; Business strength 5.2/10 and price attractiveness 3/10 retained at 30.92 USD, 9 October closing quote reverified | No new operating evidence established in accessible sources. Same operating assumptions and three-year scenario values: base 37.71 USD (+22.0%), adverse 8.07 USD (−73.9%); horizon rolls to 11 October 2029. Analytical confidence and operating tests unchanged |
| 18 October 2026 | Hers Australia integration and UK Hair launch added; Q3 report confirmed for 9 November. Closing quote 28.07 USD, 16 October. Current version 1.2: Business strength 5,2/10; price attractiveness 4,0/10 | Underlying business assessments retained; cheaper quote improves base return to +34.3%, adverse −71.2%, over three years to 18 October 2029. Operating assumptions unchanged. Prior version-1.0 ratings remain historical; no automatic point-for-point comparison |
| 25 October 2026 | Injectable and oral TRT expansion added. Closing quote 27.71 USD, 23 October. Methodology 1.2: Business strength 5,2/10 and price attractiveness 4,0/10 retained | Launch broadens the offer but does not quantify incremental economics. Unchanged operating assumptions produce a base return of +36.1% and adverse return of −70.9% over three years to 25 October 2029; the one-week quote change is insufficient for a score change |
| 1 November 2026 | Interim HHS enforcement-discretion policy and the company’s Peptides+ plans added; missed 20 October Germany launch reconciled. Closing quote 27.68 USD, 30 October. Methodology 1.2: Business strength 5,2/10 and price attractiveness 4,0/10 retained | Policy and launches expand optionality but do not yet quantify adoption or economics. Unchanged assumptions produce a base return of +36.2% and adverse return of −70.8% over three years to 1 November 2029; the 0.1% weekly quote change is immaterial |
| 8 November 2026 | Lilly agreement, Benefits expansion and first CBO appointment added. Closing quote 26.00 USD, 6 November. Methodology 1.2: Business strength remains 5,2/10, with competitive advantage raised to 5,2/10; price attractiveness rises to 4,1/10 | A second major branded GLP-1 relationship strengthens distribution evidence, but disclosed economics remain absent. Unchanged operating assumptions produce a base return of +45.0% and adverse return of −68.9% over three years to 8 November 2029; lower price improves risk/reward only modestly before Q3 results |
| 11 November 2026 | Q3 results, 10-Q and call incorporated. Revenue $890.4m, U.S. growth 21%, subscribers 2.788m (−103k sequentially), gross margin 57%, FCF $26.0m; FY EBITDA guidance reduced. Closing quote 19.13 USD, 10 November. Methodology 1.2: Business strength 5,1/10; price attractiveness 4,4/10 | Revenue demand and quarterly cash flow improve, but subscriber momentum, margins and full-year profit outlook weaken. Revised assumptions give a base return of +61.0% and adverse return of −79.5% over three years to 11 November 2029 |
| 15 November 2026 | Official Q3 transcript and presentation reviewed; Huberman board appointment and paid advisory/marketing arrangements added; FTC amended complaint adding five states incorporated. Management presents 85%+ long-term online revenue retention and 6–8 month payback for selected Q1 cohorts. Closing quote 19.73 USD, 13 November. Methodology 1.2: Business strength 5,1/10 and price attractiveness 4,4/10 retained | New information increases governance and legal scrutiny but does not change reported operating evidence. Unchanged assumptions give a base return of +56.2% and adverse return of −80.2% over three years to 15 November 2029; the 3.1% quote recovery is insufficient for a score change |
| 20 November 2026 | Peptides+ launched on 18 November with five treatments and paid Care+; the UK added a metabolic questionnaire, optional testing and Care+ on 19 November. No adoption, margin or cash contribution was disclosed. Closing quote 16.02 USD, 19 November. Methodology 1.2: Business strength remains 5,1/10; price attractiveness rises to 4,8/10 | The launches convert plans into commercial availability but do not prove demand or economics. Operating terminal assumptions remain unchanged; the lower quote produces a +92.3% base return and −75.6% adverse return over three years to 20 November 2029 |
Rating history: The 7 October qualitative view is historical, using 29.47 USD (6 October close). It contained neither standardized numerical score nor a methodology version, so it is not a comparable prior score. The 10 October entries above are the first baseline under version 1.0; no numerical score has been backfilled. The 10–11 October numerical entries retain version 1.0; the current assessment uses version 1.2. They are not a mechanically comparable point-change series, and no historical rating has been recalculated with newer evidence.
Future updates should append dated evidence and explain changes in thesis status, confidence, valuation assumptions and current view.
Review cadence: after quarterly results and material clinical, regulatory, partner or financing developments. The analysis updates evidence and proposed tests; it does not prescribe portfolio transactions.
Core sources
- HIMS Q3 2026 earnings release — reported financials, KPIs, guidance, balance sheet and reconciliations. Official release, 9 November 2026. Covers Q3 and nine months ended 30 September.
- Official HIMS Q3 2026 earnings call transcript — management claims on subscriber trends, the $18 million revenue deferral, international mix, AI rollout, investment plans and 2027 tests. Official Q3 presentation — company-defined retention, payback, customer-mix and capital-allocation metrics. Both were available on the IR results page and reviewed on 15 November.
- Q1 2026 call supplied in this project — prior guidance and branded-revenue accounting.
- Company announcement of the GLP-1 reset — 9 March 2026.
- Company AI update — 24 September 2026.
- FTC amended case record, FTC announcement, 10 November 2026, and HIMS response — allegations, addition of five state co-plaintiffs and company position; the case remains pending.
- Q3 2026 Form 10-Q — period ended 30 September 2026; revenue mix, margins, cash flow, debt, liquidity and acquisition obligations.
- CAO appointment — published 7 October 2026. Related Form 8-K, dated 7 October; transition terms checked 11 October.
- Huberman board appointment — announced 9 November 2026; Form 8-K dated 4 November — non-independent director status, board compensation and separate advisory/marketing agreements.
- Hers Australia launch — 12 October 2026; UK Hair/company update — 14 October; Germany launch — 20 October; TRT expansion — 21 October; Peptides+ statement — 29 October; HHS notice — 30 October; first CBO — 2 November; Benefits partners — 5 November; Lilly agreement — 6 November. Reported launch and agreement facts are separated from unquantified management expectations and analyst assumptions. Peptides+ launch — 18 November; Hers Peptides+ page — advertised launch pricing and regulatory disclosures; UK metabolic/Care+ launch — 19 November. Commercial availability is separated from unquantified adoption and economics.
- Q3 results — released 9 November 2026 after the NYSE close; Q3 call transcript. Next results date not searched because two calendar months have not elapsed.
- Common investment methodology — version 1.2, effective 16 October 2026; reread 20 November for both scores.
- HIMS price history — 19 November 2026 regular-session closing price of 16.02 USD, checked 20 November and corroborated by Twelve Data.
Checked 20 November 2026 — partial coverage. Peptides+ commercial launch and the UK metabolic/Care+ launch were reconciled into growth drivers, risk/evidence notes and the current Business strength rationale. They demonstrate launch execution but not adoption, margin or cash contribution, so all five business component scores remain unchanged and Business strength stays 5,1/10. Price attractiveness rises to 4,8/10 at the 19 November closing quote of 16.02 USD. With operating assumptions unchanged, the three-year base return is +92.3% and adverse return −75.6%.
Analytical uncertainties: Current organic subscriber additions and churn, specialty-level CAC/payback, cross-sell economics, unit economics for Lilly/Novo access, the return on the Huberman advisory/marketing spend, and profit contribution from international, TRT, AI and Peptides+ remain unquantified. Peptides+ launch pricing is visible, but customer adoption, treatment mix, manufacturing mix, gross margin, safety outcomes and cash contribution are not. Q4 cash flow, resolution of the FTC litigation and the 2027 outlook are still future evidence. The Q3 release, 10-Q, official call transcript and presentation, current methodology, SEC/FTC records and verified closing price provide the essential basis for both ratings.
Was this analysis useful to you?